STRS Ohio’s Denali Therapeutics DNLI Stock Holding History

STRS Ohio’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$111K	Buy	+4,300	New	+$88.4K	﹤0.01%	1841
2025 Q3	–	Sell	-14,300	Closed	-$200K	–	2220
2025 Q2	$200K	Sell	14,300 -9,500	-40%	-$134K	﹤0.01%	1661
2025 Q1	$324K	Hold	23,800	–	–	﹤0.01%	1369
2024 Q4	$485K	Buy	23,800 +6,400	+37%	+$164K	﹤0.01%	1224
2024 Q3	$507K	Hold	17,400	–	–	﹤0.01%	1256
2024 Q2	$404K	Buy	17,400 +4,400	+34%	+$84.5K	﹤0.01%	1342
2024 Q1	$266K	Sell	13,000 -800	-6%	-$15K	﹤0.01%	1477
2023 Q4	$296K	Hold	13,800	–	–	﹤0.01%	1461
2023 Q3	$284K	Hold	13,800	–	–	﹤0.01%	1469
2023 Q2	$407K	Sell	13,800 -8,100	-37%	-$228K	﹤0.01%	1368
2023 Q1	$504K	Sell	21,900 -11,800	-35%	-$325K	﹤0.01%	1311
2022 Q4	$937K	Hold	33,700	–	–	﹤0.01%	961
2022 Q3	$1.03M	Hold	33,700	–	–	﹤0.01%	879
2022 Q2	$991K	Buy	33,700 +2,800	+9%	+$73.3K	﹤0.01%	927
2022 Q1	$994K	Hold	30,900	–	–	﹤0.01%	1042
2021 Q4	$1.38M	Hold	30,900	–	–	﹤0.01%	934
2021 Q3	$1.56M	Sell	30,900 -300	-1%	-$16.9K	0.01%	836
2021 Q2	$2.45M	Buy	31,200 +4,600	+17%	+$285K	0.01%	669
2021 Q1	$1.52M	Buy	26,600 +6,800	+34%	+$455K	0.01%	878
2020 Q4	$1.66M	Buy	19,800 +7,900	+66%	+$478K	0.01%	786
2020 Q3	$426K	Hold	11,900	–	–	﹤0.01%	1421
2020 Q2	$287K	Sell	11,900 -20,900	-64%	-$491K	﹤0.01%	1547
2020 Q1	$574K	Hold	32,800	–	–	﹤0.01%	1035
2019 Q4	$571K	Hold	32,800	–	–	﹤0.01%	1380
2019 Q3	$502K	Hold	32,800	–	–	﹤0.01%	1278
2019 Q2	$680K	Buy	+32,800	New	+$735K	﹤0.01%	1035
2018 Q2	–	Sell	-4,600	Closed	-$90K	–	2132
2018 Q1	$90K	Buy	+4,600	New	+$94.6K	﹤0.01%	1639

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

STRS Ohio's DNLI Position: Q2 2026 in Review

STRS Ohio opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 4,300 shares worth $111K. The stake represents ﹤0.01% of the portfolio and ranks #1841 among its holdings. This is a return to the name: STRS Ohio previously reported a position in DNLI as recently as Q2 2025.

STRS Ohio first reported a position in DNLI in Q1 2018 and has held it in 27 quarters since. The position peaked at $2.45M in Q2 2021. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

STRS Ohio held 4,300 shares of Denali Therapeutics worth $111K as of Q2 2026.
Denali Therapeutics was a new STRS Ohio position in Q2 2026.
Denali Therapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #1841 holding.
STRS Ohio first reported a position in Denali Therapeutics in Q1 2018 and has held it in 27 quarters since.
STRS Ohio's Denali Therapeutics position peaked at $2.45M in Q2 2021.
294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.